GlassScriptPhysician profile
Glenn Ray Harris
NPI 1538245394
$2,974.73
in general payments reported to CMS, 2019-2025
25 companies · $835 in 2025
The $835 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.42 · 2020: $281 · 2022: $170 · 2023: $1,107 · 2024: $544 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,485.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $474.78 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $430.43 | 2023-2025 | |
| Esperion Therapeutics, INC. | $287.03 | 2020-2025 | Nexletol |
| Amgen INC. | $224.39 | 2022-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $201.89 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $164.83 | 2020-2025 | |
| Abbott Laboratories | $161.00 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.57 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $127.93 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $115.04 | 2019-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $91.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $79.96 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $75.97 | 2023-2024 | |
| Corcept Therapeutics | $71.80 | 2023-2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $57.88 | 2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $46.49 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.31 | 2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $42.52 | 2022-2024 | Trelegy Ellipta |
| Dynavax Technologies Corporation | $34.51 | 2024 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.21 | 2023 | |
| Grifols USA, LLC | $20.77 | 2025 | Prolastin-C Liquid |
| Si-Bone, INC. | $17.83 | 2024 | |
| Hologic Sales and Service, LLC | $16.35 | 2024 | Aptima, Thinprep 2000 Processor |
| Recordati_rare_diseases_inc. | $14.70 | 2025 | Isturisa |
| Medtronic, INC. | $14.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.